MEDIA

NEWS ARCHIVES

Interface Biologics Inc’s Chief Scientific Officer Wins Julia Levy Award
Interface Biologics Inc. (IBI), a privately held developer of transformative bio-medical polymer technology that improves the safety and effectiveness of medical devices, is proud to announce that one of it's co-founders...

Toronto, Canada, March 5, 2010 - For Immediate Release

Interface Biologics Inc. (IBI), a privately held developer of transformative bio-medical polymer technology that improves the safety and effectiveness of medical devices, is proud to announce that one of it's co-founders

Interface Biologics Inc. (IBI), a privately held developer of transformative bio-medical polymer technology that improves the safety and effectiveness of medical devices, is proud to announce that one of it's co-founders, Dr. Paul Santerre, will be awarded the Julia Levy Award at an upcoming SCI Canada Annual Awards Ceremony and Dinner, being held on March 25th in Toronto.

The Canadian section of the Society of Chemical Industry recognizes major achievements of those who have had strategic influence on the Canadian chemical industry. In a recent press release, SCI Awards Chair and GKCI President Graham Knowles stated, "These awards acknowledge outstanding contributions to development and implementation of strategies that have resulted in the strengthening of Canadian industry, academic, or research institutions in the field of chemistry" The Julia Levy award specifically recognizes successful commercialization of innovation in Canada, in the field of Bio-medical Science and Engineering, with a particular focus on the synergistic relationship between university and business.

Dr. Paul Santerre's knowledge of the body's inflammatory systems allowed him to program surface biocompatibility into raw plastic resins, well before medical device production. This has given Interface Biologics Inc. (IBI), platform technologies in the area of programmable drug delivery to control device related infections and anti-thrombogenic devices to treat vascular disease. One of these technologies has recently led to a revenue generating licence deal for anti-clotting peripherally inserted central catheters.

Interface Biologics Inc., is also pleased to announce that Dr. Roseita Esfand has been promoted to Director, Research & Development. Roseita has been with IBI for almost seven years and leads the teams overseeing both the Epidel and Kinesyx platforms.

"We are very proud of the Interface Biologics team and all that they have accomplished and we're pleased to see our co-founder, Dr. Paul Santerre, being recognized for his contributions in bringing science from University to market, ensuring that research moves beyond the laboratory and positively impacts people‚s quality of life", commented Thomas P. Reeves, President and CEO, Interface Biologics. "I also want to congratulate Dr. Esfand on her well deserved promotion".

About Interface Biologics Inc.
Interface Biologics (IBI) is an early commercial stage privately held company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. IBI's primary technology focus areas are anti-thrombogenic additives that reduce thrombosis without the need for heparin and programmable drug delivery devices.

FOR FURTHER INFORMATION PLEASE CONTACT:
Julie Fotheringham
Partner, Hageman Communications
416-951-7988
Julie.fotheringham@hageman.ca

Powered by Innovasium